28 Jan

What Are Analysts Recommending for AbbVie after Q4 2018 Results?

WRITTEN BY Margaret Patrick FEATURED IN Post-Release Earnings Reports and Healthcare

Share price movements

On January 25, AbbVie (ABBV) closed at $80.54, which is 6.22% lower than its previous closing price. The steep drop came as a reaction to the company’s Q4 2018 and fiscal 2018 results released on January 25. AbbVie closed at a premium of 3.92% as compared to its 52-week low price of $77.50, and at a discount of 36.01% as compared to its 52-week high price of $125.86. As of January 25, AbbVie’s market capitalization was $121.70 billion. The company is trading at a trailing PE ratio of 15.86x and a forward PE ratio of 9.26x.

What Are Analysts Recommending for AbbVie after Q4 2018 Results?

Based on its closing price on January 25, the company reported returns of -7.64% in the last week, -4.30% in the last month, and -2.92% in the last quarter. AbbVie also reported returns of -13.51% in the last half year, -23.67% in the last year, and -12.64% YTD.

Based on its closing price on January 25, the broader biotechnology sector represented by the iShares Nasdaq Biotechnology ETF (IBB) reported returns of -0.32% in the last week, 22.13% in the last month, and 0.32% in the last quarter. IBB also reported returns of -8.29% in the last half year, -5.57% in the last year, and 13.49% YTD. AbbVie has significantly underperformed IBB in 2019 YTD.

Analysts’ recommendations and target price

Out of the 18 analysts covering AbbVie on January 27, three analysts have rated the company as a “strong buy,” three analysts have rated the company as a “buy,” nine analysts have rated the company as a “hold,” two analysts have rated the company as a “sell,” and one analyst has rated the company as a “strong sell.”

The 12-month consensus analyst recommendation for AbbVie on January 27 is a “hold.” The 12-month consensus target price for the company is $95.47, which is 18.54% higher than its last closing price on January 25. The highest, median, and lowest target price estimates for the company are $130, $90, and $71, respectively.

In the next article, we will discuss the revenue performance of AbbVie for fiscal 2018.

Latest articles

Yesterday, Apple (AAPL) launched a newly upgraded range of its iPad Air and iPad mini devices ahead of its March 25 special event.

19 Mar

Nike Gears Up to Deliver Its Q3 2019 Results

WRITTEN BY Sharon Bailey

Nike (NKE) is scheduled to report its earnings results for the third quarter of fiscal 2019 after the market closes on March 21.

On March 18, Chesapeake Energy’s (CHK) implied volatility was 51.9%, which is ~14.7% less than its 15-day average.

19 Mar

Sprint’s Revenue and Earnings Growth

WRITTEN BY Andrew Smith

Sprint (S) reported an adjusted EPS of $0.06 in the first nine months of fiscal 2018—compared to $0.08 during the same period in fiscal 2017.

19 Mar

Oil Bulls: US Oil Exports Tend to Fall More

WRITTEN BY Robert Scott

On March 18, Brent crude oil May futures settled ~$8.2 higher than the WTI crude oil May futures. On March 11, the spread was ~$9.5.

Out of the 34 analysts covering Broadcom (AVGO), 25 analysts rated the stock a “buy,” while nine analysts rated the stock a “hold."